Professional Documents
Culture Documents
CR6 - Insulina - 2023
CR6 - Insulina - 2023
CR6 - Insulina - 2023
Intermient fasng
in people with insulin treated type 2 diabetes
THE INTERFAST-2 STUDY – A RANDOMIZED, CONTROLLED TRIAL
HbA1c ≥ 7.0 %
Intermient fasng
Intermient fasng
Total daily insulin dose (n = 22)
HbA1c ↓
≥ 0.3 IU/kg body weight
Insulin dose ↓
(n = 46)
Study duraon 12 weeks
Standard care Body weight ↓
(n = 24)
ARTICLE HIGHLIGHTS
• This study was conducted to provide robust clinical data on the effects of 12 weeks of intermittent fasting in peo-
ple with insufficiently controlled insulin-treated type 2 diabetes.
• The aim of this study was to elucidate the safety and efficacy of intermittent fasting in type 2 diabetes.
• Three days of nonconsecutive intermittent fasting for 12 weeks lowered HbA1c, body weight, and total daily insu-
lin dose while improving subjective quality of life compared to a control group.
• Our findings indicate that intermittent fasting has the potential to become a promising therapy option in people
with insufficiently controlled and insulin-treated type 2 diabetes.
Diabetes Care Volume 46, February 2023 463
OBJECTIVE
To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fast-
ing (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. 1
Interdisciplinary Metabolic Medicine Trials Unit,
RESEARCH DESIGN AND METHODS Medical University of Graz, Graz, Austria
2
Division of Endocrinology and Diabetology, Depart-
Forty-six people were randomized to an IF or control group. Dietary counseling and ment of Internal Medicine, Medical University of
continuous glucose monitoring was provided. Coprimary end points were the change Graz, Graz, Austria
in HbA1c from baseline to 12 weeks and a composite end point (weight reduction
3
CBmed – Center for Biomarker Research in Medi-
cine, Graz, Austria
‡2%, insulin dose reduction ‡10%, and HbA1c reduction ‡3 mmol/mol). 4
College of Medicine and Health Sciences, Khalifa
University, Abu Dhabi, United Arab Emirates
RESULTS 5
Research and Data Intelligence Support Center,
The IF group showed a significant HbA1c reduction (27.3 ± 12.0 mmol/mol) com- Khalifa University, Abu Dhabi, United Arab Emirates
6
Division of Cardiology, Department of Internal
pared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012).
Medicine, Medical University of Graz, Graz, Austria
The coprimary end point was achieved by 8 people in the IF and none in the con- 7
Gottfried Schatz Research Center for Cell Signaling,
trol group (P < 0.001). No severe hypoglycemia occurred. Metabolism and Aging, Molecular Biology and
Biochemistry, Medical University of Graz, Graz,
CONCLUSIONS Austria
8
BioTechMed-Graz, Graz, Austria
IF is a safe and feasible dietary option to ameliorate glycemic control while reduc-
BRIEF REPORT
9
Endocrinology Lab Platform, Division of Endocri-
ing total daily insulin dose and body weight in insulin-treated people with type 2 nology and Diabetology, Department of Internal
diabetes. Medicine and Department of Gynecology and
Obstetrics, Medical University of Graz, Graz, Austria
10
Division of Gastroenterology and Hepatology,
With the numbers of people with type 2 diabetes rising worldwide, dietary modifica- Medical University of Graz, Graz, Austria
tions provide an essential therapeutic approach for blood glucose, weight, and cardio- Corresponding author: Harald Sourij, ha.sourij@
medunigraz.at
vascular risk-factor management (1,2). Intermittent fasting (IF) has emerged as an
Received 18 August 2022 and accepted 15
alternative to classic daily caloric reduction (3). The approaches to IF range from limit- November 2022
ing food consumption to certain hours of the day to alternate-day fasting (4,5). People Clinical trial reg. no. DRKS00018070, Deutschen
with insulin-treated type 2 diabetes often struggle with weight gain (6), resulting in a Register Klinischer Studien (DRKS)
vicious cycle of increasing insulin doses required to overcome the insulin resistance, This article contains supplementary material online
leading to further weight gain, and ultimately resulting in higher cardiovascular risk at https://doi.org/10.2337/figshare.21563463.
(7). A recent meta-analysis suggested IF as an appropriate diet strategy in people with © 2023 by the American Diabetes Association.
type 2 diabetes; however, the risk of hypoglycemia during fasting states in insulin- Readers may use this article as long as the
treated individuals remains a crucial barrier to adhere to diets demanding caloric re- work is properly cited, the use is educational
and not for profit, and the work is not altered.
striction and further randomized controlled trials are required to verify its feasibility More information is available at https://www.
and safety in this population (8). diabetesjournals.org/journals/pages/license.
464 IF in Insulin-Treated Type 2 Diabetes Diabetes Care Volume 46, February 2023
We hypothesized that 12 weeks of IF study protocol was published previously caloric restriction. There was no restriction
could improve glycemic control and de- (9). Briefly, this study included volunteers, on macronutrient composition or on the
crease body weight while being safe to aged between 18 and 75 years (both in- consumption of water, unsweetened cof-
practice in people with insulin-treated clusive), with insulin-treated type 2 diabe- fee, and tea without milk. On eating days,
type 2 diabetes compared with a control tes, an HbA1c $53 mmol/mol ($7.0%), participants were allowed to consume any
group. and a daily insulin dose of $0.3 IU/kg type of food or drink without any caloric re-
body wt. striction. Both groups had a comparable
RESEARCH DESIGN AND METHODS The IF group practiced IF 3 days a week, number of interactions with the study staff.
This open, single-center, randomized, con- reducing their calories on these days by All participants were switched to the
trolled trial, Intermittent fasting in sub- 75% (i.e., consuming only 25% of the rec- same basal insulin (insulin glargine U300)
jects with insulin-treated type 2 diabetes ommended caloric intake). Ingestion was prior to the randomization. The basal in-
mellitus (INTERFAST-2), was conducted at only allowed at breakfast and/or lunch to sulin was administered in the morning.
the University Hospital Graz, Graz, Austria, maintain an 18-h period of fasting. Partici- For fasting days, participants were in-
and approved by the ethics committee of pants were asked to keep a food diary to structed to reduce basal insulin by 20%
the Medical University of Graz, Graz, Aus- monitor adherence. On the remaining and prandial insulin was only adminis-
tria (EK 30-350 ex 17/18). The detailed 4 days, participants of the IF group had no tered for glucose correctional reasons. To
Excluded (n=1)
i Not meeting inclusion criteria (n=1)
i Declined to participate (n=0)
i Other reasons (n=0)
Randomized (n=46)
Allocation
Allocated to intervention (n=24) Allocated to intervention (n=22)
i Received allocated intervention (n=24) i Received allocated intervention (n=22)
i Did not receive allocated intervention (give i Did not receive allocated intervention (give
reasons) (n=0) reasons) (n=0)
Follow-Up
Lost to follow-up (give reasons) (n=0) Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0) Discontinued intervention (give reasons) (n=2)
Analysis
Analysed (n=24) Analysed (n=22)
i Excluded from analysis (give reasons) (n=0) i Excluded from analysis (give reasons) (n=0)
2.5
* meta-analyses demonstrated similar HbA1c-
reducing potential of IF compared with con-
tinuous calorie restriction in people with
type 2 diabetes, while the weight loss ap-
peared to be more pronounced (8,13)
0 with IF. Mechanistic studies suggest that
prolonged fasting might have additional
HbA1c change [mmol/mol]
A 100
B 100
***
*
HbA1c reducon ≥ 3 mmol/mol
60 %
50 50
25 %
25 25
0 0
Control Fasng Control Fasng
C D
100 *** 100
80 %
Combined Endpoint achieved
75 75
Weight reducon ≥ 2 %
***
50 50
40 %
25 25
4%
0 0
Figure 3—Coprimary end point; percentage of participants achieving each individual aspect and the combined coprimary end point. *P < 0.05,
***P < 0.001.
dosing adjustment algorithm together Medical University of Graz, Graz, Austria) for her F.Az., and A.Ou. contributed to the statistical
with isCGM data and metabolomics anal- help with the sample size calculation, and the analysis. N.J.T. and H.S. significantly contributed
team of the Endocrinology Lab Platform (Medi- to development of the study protocol. N.J.T. and
ysis of IF induced changes. We also mon- cal University of Graz, Graz, Austria), especially H.S. contributed to acquiring ethical approval
itored the RMR and physical activity Cornelia Missbrenner and Dorrit M€ unzer-Ornik. for the trial. F.Az., A.M., and H.S. had access to
throughout the study, which remained Funding. The study was funded by the Austrian and verified the raw data. M.S. is the dietitian
unchanged. Science Fund (FWF) Programme Clinical Research of the trial. H.H. and T.M. performed the me-
grants KLI 851-B and KLI-1076 to H.S. and by tabolomics analysis. H.S. conceived the trial. All
Our data demonstrate that IF over 12 authors reviewed and contributed to the final
grants P28854, I3792, DK-MCD W1226, and DOC-
weeks in insulin-treated people with type 2 130 to T.M. T.M. was supported by Austrian Re- manuscript. A.Ob. and H.S are the guarantors
diabetes is safe, reduces HbA1c, body search Promotion Agency (FFG) grants 864690 of this work and, as such, had full access to all
weight, and total daily insulin dose, while and 870454, the Integrative Metabolism Research data in the study and take responsibility for the
Center Graz, Austrian Infrastructure Program integrity of the data and the accuracy of the
RMR and the physical activity levels re-
2016/2017, the Styrian Government (Zukunfts- data analysis.
mained unaltered. Prior Presentation. Parts of this study were
fonds, doc.funds program), the City of Graz, and
BioTechMed-Graz (Flagship project DYNIMO). presented in abstract form at the 58th Euro-
Duality of Interest. No potential conflicts of pean Association for the Study of Diabetes
Acknowledgments. The authors are very grate- interest relevant to this article were reported. (EASD) Annual Meeting, Stockholm, Sweden,
ful to the study participants for their cooperation, Author Contributions. A.Ob. wrote the final 19–23 September 2022.
Angela Jacan (Center for Biomarker Research in manuscript. A.Ob. and N.J.T. contributed to effi-
Medicine, CBmed, Graz, Austria) for her contribu- cient project management and day-to-day opera- References
tion to the development of the earliest version of tion. A.Ob., N.J.T., P.N.P., H.K., F.Az., A.M., F.Ab., 1. Zhou B, Lu Y, Hajifathalian K, et al. NCD Risk
the study protocol, Dr. Regina Riedl (Institute for C.S., T.P., B.O.-P., and V.S. contributed to collec- Factor Collaboration (NCD-RisC). Worldwide trends
Medical Informatics, Statistics and Documentation, tion, analysis, and interpretation of data. A.Ob., in diabetes since 1980: a pooled analysis of 751
468 IF in Insulin-Treated Type 2 Diabetes Diabetes Care Volume 46, February 2023
population-based studies with 4.4 million participants. in type 2 diabetes. Prog Cardiovasc Dis 2017; 13. Borgundvaag E, Mak J, Kramer CK. Metabolic
Lancet 2016;387:1513–1530 60:422–434 impact of intermittent fasting in patients with
2. Davies MJ, D’Alessio DA, Fradkin J, et al. 8. Wang X, Li Q, Liu Y, Jiang H, Chen W. type 2 diabetes mellitus: a systematic review and
Management of hyperglycemia in type 2 diabetes, Intermittent fasting versus continuous energy- meta-analysis of interventional studies. J Clin
2018. A Consensus Report by the American Diabetes restricted diet for patients with type 2 diabetes Endocrinol Metab 2021;106:902–911
Association (ADA) and the European Association for mellitus and metabolic syndrome for glycemic 14. Anton SD, Moehl K, Donahoo WT, et al.
the Study of Diabetes (EASD). Diabetes Care 2018; control: a systematic review and meta-analysis of Flipping the metabolic switch: understanding and
41:2669–2701 randomized controlled trials. Diabetes Res Clin applying the health benefits of fasting. Obesity
3. Barnosky AR, Hoddy KK, Unterman TG, Varady Pract 2021;179:109003 (Silver Spring) 2018;26:254–268
KA. Intermittent fasting vs daily calorie restriction 9. Obermayer A, Tripolt NJ, Pferschy PN, et al. 15. Cienfuegos S, Gabel K, Kalam F, et al. Effects of
for type 2 diabetes prevention: a review of human INTERmittent FASTing in people with insulin- 4- and 6-h time-restricted feeding on weight and
findings. Transl Res 2014;164:302–311 treated type 2 diabetes mellitus—the INTERFAST- cardiometabolic health: a randomized controlled
4. Evert AB, Dennison M, Gardner CD, et al. 2 study protocol. Diabet Med 2022;39:e14813 trial in adults with obesity. Cell Metab 2020;32:
Nutrition therapy for adults with diabetes or 10. Reisinger AC, Posch F, Hackl G, et al. 366–378.e3
prediabetes: a consensus report. Diabetes Care Branched-chain amino acids can predict mortality 16. Gabel K, Hoddy KK, Haggerty N, et al. Effects
2019;42:731–754 in ICU sepsis patients. Nutrients 2021;13:3106 of 8-hour time restricted feeding on body weight
5. Varady KA, Cienfuegos S, Ezpeleta M, Gabel K. 11. Carter S, Clifton PM, Keogh JB. Effect of and metabolic disease risk factors in obese
Clinical application of intermittent fasting for intermittent compared with continuous energy adults: a pilot study. Nutr Healthy Aging 2018;4:
weight loss: progress and future directions. Nat restricted diet on glycemic control in patients 345–353
Rev Endocrinol 2022;18:309–321 with type 2 diabetes: a randomized noninferiority 17. Elhadd T, Bashir M, Baager KA, et al.; PROFAST
6. Balkau B, Home PD, Vincent M, Marre M, trial. JAMA Netw Open 2018;1:e180756 Ramadan Study Group. Mitigation of hypoglycemia
Freemantle N. Factors associated with weight 12. Li C, Sadraie B, Steckhan N, et al. Effects of a during Ramadan using the flash glucose monitoring
gain in people with type 2 diabetes starting on one-week fasting therapy in patients with type-2 system following dose adjustment of insulin and
insulin. Diabetes Care 2014;37:2108–2113 diabetes mellitus and metabolic syndrome—a sulphonylurea in patients taking multiple glucose-
7. Herman ME, O’Keefe JH, Bell DSH, Schwartz randomized controlled explorative study. Exp Clin lowering therapies (The PROFAST-IT Study). Diabetes
SS. Insulin therapy increases cardiovascular risk Endocrinol Diabetes 2017;125:618–624 Res Clin Pract 2021;172:108589